DELIC HOLDINGS CORP - DELCF STOCK NEWS

Delic Holdings Inc. (CSE: DELC, OTCQB: DELCF) announced on June 8, 2021, a definitive agreement to acquire Ketamine Infusion Centers LLC (KIC) for USD$3,050,000. KIC, operating two clinics in Phoenix and Bakersfield, reported revenues exceeding USD$1.5 million since 2019. This acquisition will enhance DELIC's presence in the psychedelics market and leverage its media platform to drive patient acquisition. KIC's expansion plans aim to double its locations, tapping into the growing demand for ketamine treatments.

Delic Holdings Inc. (DELC, OTCQB: DELCF) has successfully acquired Complex Biotech Discovery Ventures Ltd. (CBDV) for $7 million, which will be rebranded as Delic Labs. This strategic acquisition aims to enhance the company's capabilities in psilocybin and cannabis R&D, leveraging CBDV's expertise in extraction and testing. With a profitable history, CBDV boasts over 50 blue-chip clients and aims to innovate within the psychedelic wellness sector as legalization progresses. The deal includes potential earn-outs based on revenue milestones, promoting future growth.

Delic Holdings Inc. (DELIC, OTCQB: DELCF) announced the closure of a non-brokered private placement by its acquisition target, Complex Biotech Discovery Ventures Ltd. (CBDV), raising CAD$3,432,356 through the sale of 11,441,189 subscription receipts at CAD$0.30 each. Subscription receipts convert into common shares and warrants upon completing acquisition conditions before June 30, 2021. Proceeds will enhance DELIC's cash position and support business operations.

Delic Holdings is set to acquire two additional licensed ketamine clinics in Arizona, which will double its infusion chain size and establish it as the largest operator in the state. The acquisition aligns with Delic's strategy to enhance patient access to treatment for anxiety, depression, and PTSD. Ketamine Infusion Centers has overseen over 4,000 treatments and generated more than $1.5 million in revenue. Upon completion, KIC will operate three clinics in Arizona and one in California, expanding service delivery for critical wellness treatments.

Delic Holdings Inc. (CSE: DELC, OTCQB: DELCF) issued a statement confirming no material undisclosed information regarding recent news and promotional activities related to its shares. The company engaged IDR Marketing, Inc. for financial marketing to increase investor awareness. Delic emphasizes that all promotional materials were factual and based on public disclosures. Since its listing on November 18, 2020, Delic has partnered with various investor relations firms. Management reported no recent transactions involving its directors or officers' securities.

Delic Holdings Inc. (DELIC) has announced that its acquisition target, Complex Biotech Discovery Ventures Ltd. (CBDV), has appointed Dr. Eric Janusson as Lead Chemist. Dr. Janusson specializes in analytical chemistry and will lead efforts in method development for cannabis and psilocybin testing. Additionally, DELIC and CBDV plan a private placement for a minimum of 3,333,333 subscription receipts at CAD$0.30 each, enabling collaboration and growth in the psychedelic wellness sector.

Delic Holdings Inc. (DELIC, DELCF) has reported transformative growth in Q1 2021, executing its M&A strategy with key acquisitions including Ketamine Infusion Center (KIC) and Complex Biotech Discovery Ventures (CBDV). KIC, with over 4,000 treatments and revenues exceeding USD$1.5mm, aims to expand from 2 to up to 18 clinics in the next 12-18 months. CBDV will be renamed DELIC Labs, focusing on psilocybin and cannabis research. Additionally, the acquisition of Homestead enhances product offerings and expands accessibility in the psychedelic market. A new date for the Meet DELIC conference in Las Vegas will be announced soon.

Delic Holdings Inc. (DELCF) announces that its acquisition target, Complex Biotech Discovery Ventures Ltd. (CBDV), has commercialized its Advanced Analytical Testing services, receiving its first research orders via a new online payment platform. This launch allows clients to conveniently order various tests related to cannabis, enabling a more streamlined experience in chemical analytics. The service aims to enhance product development in the cannabis industry, leveraging CBDV's expertise at the University of British Columbia.

Delic Holdings (DELCF) has appointed John Coleman, PhD, as Vice President of Business Development, enhancing its leadership team. Coleman, previously President of Anandia Labs, brings extensive experience in biotechnology and drug development. His background includes co-founding Anandia Labs and leadership roles in various pharmaceutical companies. The Board approved 250,000 stock options for Coleman at $0.55. This strategic hiring aims to strengthen DELIC's position in the psychedelic wellness sector.